A randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI
Background Ischemia-reperfusion injury remains a major clinical problem in patients with ST-elevation myocardial infarction (STEMI), leading to myocardial damage despite early reperfusion by primary percutaneous coronary intervention (PPCI). There are no effective therapies to limit ischemia-reperfu...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Journal article |
語言: | English |
出版: |
Elsevier
2021
|